Retatrutide vs Survodutide: Head-to-Head Comparison
Both are investigational next-generation peptides for obesity. Retatrutide is a triple agonist (GIP/GLP-1/glucagon) with up to 24.2% weight loss — the highest ever reported. Survodutide is a dual agonist (GLP-1/glucagon) with up to 19% weight loss and strong MASH data. Neither is FDA-approved yet.
Side-by-Side Comparison
| Dimension | Retatrutide | Survodutide |
|---|---|---|
| Evidence Level | Level B — Phase 2 RCT; Phase 3 ongoing (TRIUMPH) | Level B — Phase 2 data; Phase 3 ongoing (SYNCHRONIZE) |
| FDA Status | Not approved; Eli Lilly Phase 3 | Not approved; Boehringer Ingelheim Phase 3 |
| Weight Loss Efficacy | Up to 24.2% (Phase 2 at 48 weeks) | Up to 19% (Phase 2 at 46 weeks) |
| Mechanism | Triple agonist: GIP + GLP-1 + glucagon | Dual agonist: GLP-1 + glucagon |
| Liver Fat / MASH Benefit | Significant liver fat reduction observed | Significant liver fat reduction; dedicated MASH trials |
| Diabetes Efficacy | HbA1c reduction up to 2.16% in Phase 2 | Glycemic improvements observed; less diabetes-specific data |
Peptide Overviews
Retatrutide
BHuman StudiesRetatrutide is an investigational triple-hormone receptor agonist developed by Eli Lilly. It simultaneously targets GIP, GLP-1, and glucagon receptors, achieving the highest weight loss ever reported in an obesity clinical trial — up to 24.2% at 48 weeks.
Survodutide
BHuman StudiesSurvodutide is a dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim. In Phase 3 trials, it demonstrates significant weight loss and is also being investigated for metabolic dysfunction-associated steatohepatitis (MASH/NAFLD).
Retatrutide vs Survodutide: FAQ
Stay Informed on Peptide Research
Get weekly comparison updates, new study alerts, and regulatory changes.
No spam. Unsubscribe anytime.
Medical Disclaimer
This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.
No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.